 Sydney, Sept. 01, 2021 GLOBE NEWSWIRE -- SYDNEY, AUSTRALIA 1 September 2021 Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company, a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces that the last patient has been enrolled and safely dosed in Stage 2 of Part B of its Phase II TACTI-002 study also designated KEYNOTE-798. This completes the recruitment of 2nd line PD-1PD-L1 refractory non-small cell lung cancer NSCLC patients into the trial. 